PHC Holdings (TYO:6523) said it will transfer the commercial operations of the Eversense continuous glucose monitoring system from its subsidiary Ascensia Diabetes Care to Senseonics Holdings, according to a Monday filing on the Tokyo Stock Exchange.
The move is part of PHC's portfolio review under its Value Creation Plan 2027, aimed at improving investment efficiency.
The company said further growth of Eversense would require sustained investment and that integrating development, manufacturing and sales under Senseonics would be more efficient.